Regen BioPharma, Inc. (RGBP)

Market Cap	195.43K -87.2%
Revenue (ttm)	236.56K
Net Income	-1.73M
EPS	-0.04
Shares Out	177.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	7,622,967
Open	0.0011
Previous Close	0.0011
Day's Range	0.0010 - 0.0011
52-Week Range	0.0010 - 0.1169
Beta	2.67
RSI	30.96
Earnings Date	Apr 17, 2026

About Regen BioPharma

Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to immune cell activation for oncology applications and immune cell suppression for autoimmune diseases. It also develops several products: HemaXellarate, a cellular therapeutic product derived from autologous stromal vascular fraction from adipose tissue; dCellVax, an autologous dendritic cell treated with an siRNA inhibitor of indoleamine-2,3-dioxy...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 1
• Stock Exchange: OTCMKTS
• Ticker Symbol: RGBP

Financial Performance

In fiscal year 2025, Regen BioPharma's revenue was $236,561, an increase of 0.00% compared to the previous year's $236,560. Losses were -$1.27 million, 90.7% more than in 2024.